ABVC Biopharma, Inc. announced the enrollment progress in the Phase II Part II clinical study of the Company's ADHD medicine (ABV-1505). Since results on the first subject treated were reported on May 10, 2022, a total of 22 subjects have been enrolled in the study from a total of 32 subjects screened. One of the enrolled participants from the three arms completed the 8- week treatment per the study design. The study, a randomized, double-blind, placebo-controlled study, titled "A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II," is expected to eventually enroll approximately 100 patients. Five prestigious research hospitals in Taiwan and the research hospital at the University of California, San Francisco are participating in the study, which is a continuation of the Phase II Part I study of ABV-1505, completed successfully at UC, San Francisco and accepted by the U.S. Food & Drug Administration in October 2020.